Navigation Links
Savient Submits Biologics License Application (BLA) for pegloticase
Date:10/31/2008

EAST BRUNSWICK, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the submission of its BLA to the U.S. Food and Drug Administration (FDA) seeking approval to market pegloticase in the United States along with its request for a priority review. Savient's filing includes data from both the six-month placebo controlled Phase 3 pivotal trials, as well as data from the Open Label Extension (OLE) study. The data set includes 101 patients with at least twelve months continuous treatment.

"Filing the BLA for pegloticase is a major milestone for Savient," said Christopher Clement, President and Chief Executive Officer. "This filing reflects our commitment to changing the paradigm of therapy available to the treatment-failure gout population and brings us one step closer to commercializing this drug and offering a solution to patients who suffer from this debilitating disease."

The two replicate, six-month, Phase 3 clinical trials for pegloticase were performed under the auspices of a Special Protocol Assessment (SPA) and pegloticase was granted Orphan Drug designation by the FDA. The OLE study was established to allow patients who completed the Phase 3 program the opportunity to continue to receive pegloticase for an extended period of time.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... equipment, trained personnel, and detection dogs to safeguard ... A revolutionary new electronic chip with nano-sized chemical ... easier. , The groundbreaking nanotechnology-inspired sensor, devised by ... School of Chemistry and Center for Nanoscience and ... picks up the scent of explosives molecules better ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
Breaking Biology Technology:Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... a largely unseen battle now raging in the workplace. It ... are managers who covet the traditional employment deal money, ... commitment to playing the organizational game by traditional rules, e.g., ... unquestioning willingness to do whatever the business requires. Only Type ...
... University of Wisconsin-Madison leads the nation in the number ... in 2006. UW-Madison's total this year is up to ... ,The foundation bestows the awards on young researchers in ... biology, neuroscience and physics. Sloan Fellowships carry a two-year, ...
... Defense Agency, an information security consulting firm headquartered here ... been chosen to challenge eight student teams in an ... complexity and sophistication, so it's essential to support collegiate ... of cyber defenders," said Sami Saydjari, president and founder ...
Cached Biology Technology:Who will win the battle to redefine the workplace? 2Who will win the battle to redefine the workplace? 3Who will win the battle to redefine the workplace? 4Who will win the battle to redefine the workplace? 5UW-Madison has 7 Sloan research fellows, top in nation 2
(Date:7/25/2014)... MA A study published online in the ... a novel approach to preventing cervical cancer based on ... cancer after removal of a discrete population of cells ... a study that looked at squamocolumnar junction cells, or ... and have been implicated as the origins of cervical ...
(Date:7/25/2014)... professor of biomedical engineering at the University of ... engineering and artificial organ development., "Introduction to Tissue ... to entering into the field of artificial organ ... biomedical engineering at UH, served as a series ... there are other published books on the subject ...
(Date:7/25/2014)... has opened the way for the development of new lines ... annual barley production is second only to wheat with 7-8 ... most important diseases of barley. , Senior Research Scientist Dr ... growths on the cell walls of barley plants that block ... research, by the ARC Centre of Excellence in Plant Cell ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... from the atmosphere are unlikely to offer an economically feasible ... to a report issued by the American Physical Society and ... not kid ourselves that we can pour all the carbon ... it out later at little cost," said Socolow, a professor ...
... scientists have discovered how two closely related proteins guide ... and repelling these axons as they navigate the most ... make remarkably precise connections. The discovery, reported April ... proteins belonging to the "semaphorin" family of guidance cues ...
... of Botany (KIB), part of the Chinese Academy of ... Natural Products and Bioprospecting (NPAB). As a ... in the SpringerOpen portfolio, available on www.springerlink.com . ... Science (CLoS), a collection comprising more than 90 English-language ...
Cached Biology News:Report: Direct removal of carbon dioxide from air likely not viable 2Johns Hopkins scientists reveal nerve cells' navigation system 2Johns Hopkins scientists reveal nerve cells' navigation system 3New SpringerOpen journal from the Chinese Academy of Sciences 2